pharmaphorum August 30, 2024
Phil Taylor

Emergent BioSolutions has been given FDA approval to extend the indications for its smallpox vaccine ACAM2000 to include the prevention of mpox, currently deemed a public health emergency by the WHO.

ACAM200 can be used for people at high risk of mpox, according to the company, with the news causing shares in Emergent to spike more than 27% in pre-market trading. The virus that causes mpox (previously known as monkeypox) is in the same Orthopox group as the one that causes smallpox.

The approval comes as there were 1,000 new cases of mpox reported this week in the Democratic Republic of the Congo (DRC) alone, which is at the heart of the current outbreak, with cases also seen in a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article